These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35476146)

  • 1. Neuroendocrine hepatic metastatic disease: the surgeon's perspective.
    Concors SJ; Maxwell JE
    Abdom Radiol (NY); 2022 Dec; 47(12):4073-4080. PubMed ID: 35476146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
    Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
    Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
    Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum.
    Gudmundsdottir H; Fogliati A; Grotz TE; Thiels CA; Warner SG; Smoot RL; Truty MJ; Kendrick ML; Nagorney DM; Halfdanarson TR; Cleary SP; Starlinger P
    Ann Surg Oncol; 2024 Aug; 31(8):5370-5376. PubMed ID: 38689169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery.
    Jaeck D; Oussoultzoglou E; Bachellier P; Lemarque P; Weber JC; Nakano H; Wolf P
    World J Surg; 2001 Jun; 25(6):689-92. PubMed ID: 11376398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number of Hepatic Resections and Association with Complication after Metastatic Neuroendocrine Tumor Debulking: An American College of Surgeons NSQIP Database Study.
    Schwarz JL; Kuchta KM; Rojas A; Mehdi S; Hoon Choi S; Keutgen XM; Talamonti MS; Hogg ME
    J Am Coll Surg; 2023 Jul; 237(1):157-168. PubMed ID: 37022773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.
    Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
    Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
    Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
    J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
    Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small bowel neuroendocrine neoplasm: what surgeons want to know.
    Gupta A; Lubner MG; Liu JB; Richards ES; Pickhardt PJ
    Abdom Radiol (NY); 2022 Dec; 47(12):4005-4015. PubMed ID: 35312820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.
    Mayo SC; de Jong MC; Pulitano C; Clary BM; Reddy SK; Gamblin TC; Celinksi SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Ferrero A; Schulick RD; Choti MA; Mentha G; Strub J; Bauer TW; Adams RB; Aldrighetti L; Capussotti L; Pawlik TM
    Ann Surg Oncol; 2010 Dec; 17(12):3129-36. PubMed ID: 20585879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
    Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
    Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Furukawa T; Ozaka M; Takamatsu M; Takazawa Y; Inamura K; Inoue Y; Mie T; Takeda T; Kanata R; Kasuga A; Matsuyama M; Sasaki T; Takahashi Y; Sasahira N
    Int J Surg Pathol; 2021 Aug; 29(5):475-481. PubMed ID: 33543658
    [No Abstract]   [Full Text] [Related]  

  • 20. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
    Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.